# US 11,110,070 B2 · Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,110,070 B2
- Document ID: US11110070B2
- Status: Granted
- Kind: B2
- Application number: 15/776,880
- Filed: 2016-11-17
- Published: 2018-11-15
- Granted: 2021-09-07
- Earliest claimed: 2015-11-17
- Assignees: The Trustees of Columbia University in the City of New York
- Applicants: The Trustees of Columbia University in the City of New York
- Inventors: Rebecca Anne Brachman; Christine Ann Denny; René Hen
- Web page: https://patentgrep.com/patent/US11110070B2

## CPC

- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0043: {Nose}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/401: Proline; Derivatives thereof, e.g. captopril
- A61K 31/42: Oxazoles
- A61K 31/4245: Oxadiazoles
- A61K 31/428: condensed with carbocyclic rings
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/453: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for prophylactically treating a stress-induced affective disorder or stress-induced psychopathology in a subject are provided. Also provided are methods for inducing and/or enhancing stress resilience in a subject. In certain embodiments, an effective amount, of an antagonist of the glutamate N-methyl-D-aspartate (NMDA) receptor, such as ketamine, or a pharmaceutically acceptable salt or derivative thereof, is administered to a subject prior to a stressor.

## Claims

### Claim 1

A method for preventing or delaying a stress-induced affective disorder or stress-induced psychopathology in a subject, the method consisting of administering, once or twice, an effective amount of a pharmaceutic composition consisting of ketamine to the subject, wherein the method consists of administering the pharmaceutic composition to the subject 1 week prior to the stressor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmaceutic composition is administered to the subject once prior to a stressor.

### Claim 3 (depends on 1)

The method of claim 1, wherein the pharmaceutic composition is administered orally, intravenously, intranasally, or via injection to the subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein the stress-induced affective disorder comprises major depressive disorder and/or posttraumatic stress disorder (PTSD).

### Claim 5 (depends on 1)

The method of claim 1, wherein the stress-induced affective disorder is selected from the group consisting of: depressive-like behavior and associated affective disorders, anhedonic behavior and associated affective disorders, anxiety and associated affective disorders, cognitive impairments and deficits and associated disorders, fear, and combinations thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the stress-induced affective disorder comprises stress-induced psychopathology.

### Claim 7 (depends on 6)

The method of claim 6, wherein the stress-induced psychopathology comprises depressive and/or anxious behavior.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject is a human.